Auranofin (Standard)

Auranofin (Standard) is the analytical standard of Auranofin. This product is intended for research and analytical applications. Auranofin (SKF-39162) is a thioredoxin reductase (TrxR) inhibitor with an IC50 of 0.2 μM. Auranofin exhibits antiviral activity against SARS-CoV21, with a CC50 of 4.2 μM for monkey kidney Vero E6 cells.

Product Specifications

CAS Number

[34031-32-8]

UNSPSC

12352100

Target

Bacterial; Reference Standards; SARS-CoV

Related Pathways

Anti-infection; Others

Field of Research

Cancer; Infection; Inflammation/Immunology

Smiles

CC(O[C@@H]([C@@H]([C@H]1COC(C)=O)OC(C)=O)[C@H]([C@@H](O1)[S-][Au+][P](CC)(CC)CC)OC(C)=O)=O

Molecular Formula

C20H34AuO9PS

Molecular Weight

678.48

References & Citations

[1]Cox AG, et al. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol. 2008 Oct 30;76 (9) :1097-109.|[2]Park SH, et al. Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. Int J Oncol. 2014 Oct;45 (4) :1691-8.|[3]Park N, et al. Auranofin promotes mitochondrial apoptosis by inducing annexin A5 expression and translocation in human prostate cancer cells. J Toxicol Environ Health A. 2014;77 (22-24) :1467-76.|[4]Lee JC, et al. Effect of auranofin treatment on aberrant splenic interleukin production in adjuvant arthritic rats. J Immunol. 1987 Nov 15;139 (10) :3268-74.|[5]Shuofeng Yuan, et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters. Nat Microbiol. 2020 Oct 7.